Home › Ulcerative Colitis › Ohio
Ulcerative Colitis clinical trials in Ohio
26 studies for Ulcerative Colitis are looking for participants at sites in Ohio.
Cities in Ohio
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-025, Brunswick
- Site US-023, Dayton
- Site US-027, Westlake
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07845487Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Dayton Gastroenterology - Englewood /ID# 284065, Englewood
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Beavercreek
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT06619990A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Sep 25, 2026 · NCT06663332A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Cleveland Clinic, Cleveland
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Sep 24, 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Ohio State University, Hilliard
- DSI Research, LLC d/b/a ObjectiveHealth Clinical Research - Springboro, Springboro
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Dayton Gastroenterology, LLC, Dayton
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07186101A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- University Hospitals Cleveland Medical Center /ID# 271831, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 22, 2026 · NCT07071519Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Cleveland Clinic Foundation, Cleveland
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 21, 2026 · NCT07513181A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Gastro Intestinal Research Institute of Northern Ohio, LLC., Westlake
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- North Shore Gastroenterology Research - Site Number: 8400130, Westlake
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- and 3 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT06581328A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Great Lakes Gastroenterology Research, LLC, Mentor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology & Hepatology Specialists, Inc. - Site Number: 8400139, Canton
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- and 4 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- GCGA Physicians, LLC dba / Gastro Health Research, Cincinnati
- NexGen Research, Lima
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 30, 2026 · NCT06598943An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- University of Cincinnati College of Medicine, Cincinnati
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
RecruitingObservational study
Ages 18 to 64 · All sexes · Updated Jul 9, 2026 · NCT06398626A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital, Cleveland
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2
Ages 12 to 17 · All sexes · Updated Jul 8, 2026 · NCT05287126A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
- Gastro Intestinal Research Institute of Northern Ohio,, Westlake
RecruitingObservational studyHealthy volunteers welcome
Ages 22 and older · All sexes · Updated Apr 28, 2026 · NCT06810518A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recruiting
Ages 13 to 17 · All sexes · Updated Nov 21, 2025 · NCT07195123Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- University of Cincinnati, Cincinnati
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 8, 2025 · NCT06750731From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.